Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib vs placebo after docetaxel failure in metastatic hormone‑refractory prostate cancer (AUPSG)
2007-002370-64Phase 2Completed
- Sponsor
- Austrian Prostate Study Group
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Sorafenib + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: 12-week disease stabilization rate. Started Jun 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2007-002370-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002370-64.